Considerations For Early Stage Gene Therapy Start-Ups: From Clinical Development To Manufacturing To Commercialization

In 2020, nearly $20 billion of funding poured into the advanced therapy sector, reflecting the enthusiasm of researchers and investors in the transformative potential of these novel treatments.

Recently, Precision ADVANCE hosted Considerations for Early Stage Gene Therapy Start-ups: From Clinical Development to Manufacturing to Commercialization, an expert panel discussion moderated by Anshul Mangal, President of Project Farma and Precision ADVANCE. Precision ADVANCE is a collection of interconnected services and complementary teams uniquely focused on the complexities of gene therapies and the resources needed to bring these advanced therapeutics successfully to market.